Journal of Gastroenterology

, Volume 46, Issue 4, pp 501–509

High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b

Authors

    • Department of GastroenterologyOgaki Municipal Hospital
  • Takashi Kumada
    • Department of GastroenterologyOgaki Municipal Hospital
  • Seiki Kiriyama
    • Department of GastroenterologyOgaki Municipal Hospital
  • Makoto Tanikawa
    • Department of GastroenterologyOgaki Municipal Hospital
  • Yasuhiro Hisanaga
    • Department of GastroenterologyOgaki Municipal Hospital
  • Akira Kanamori
    • Department of GastroenterologyOgaki Municipal Hospital
  • Toshifumi Tada
    • Department of GastroenterologyOgaki Municipal Hospital
  • Takahiro Arakawa
    • Department of GastroenterologyOgaki Municipal Hospital
  • Masashi Fujimori
    • Department of GastroenterologyOgaki Municipal Hospital
  • Takuro Niinomi
    • Department of GastroenterologyOgaki Municipal Hospital
  • Naoto Ando
    • Department of GastroenterologyOgaki Municipal Hospital
  • Satoshi Yasuda
    • Department of GastroenterologyOgaki Municipal Hospital
  • Keisuke Sakai
    • Department of GastroenterologyOgaki Municipal Hospital
  • Jun Kimura
    • Department of GastroenterologyOgaki Municipal Hospital
Original Article—Liver, Pancreas, and Biliary Tract

DOI: 10.1007/s00535-010-0328-z

Cite this article as:
Toyoda, H., Kumada, T., Kiriyama, S. et al. J Gastroenterol (2011) 46: 501. doi:10.1007/s00535-010-0328-z

Abstract

Background

The ability to predict the outcome of peginterferon (PEG-IFN) and ribavirin combination therapy based on the reduction in hepatitis C virus (HCV) RNA levels at 4 weeks after starting the therapy and amino acid substitutions in HCV was to be confirmed.

Methods

We measured the reduction in HCV RNA levels at 4 weeks after starting the combination therapy, as well as examining amino acid substitutions at residue 70 in the HCV core and within the interferon sensitivity-determining region (ISDR) of HCV non-structural protein 5A (NS5A), for 101 patients infected with HCV genotype 1b. The ability of these factors to predict a sustained virologic response (SVR) was analyzed.

Results

When a 3 log10 reduction in HCV RNA levels at 4 weeks after starting therapy was set as the cut-off value, an SVR was achieved in 37 of the 46 patients (80.4%) with a ≥3 log10 decrease and in 4 of the 55 patients (7.3%) with a <3 log10 decrease. All 4 patients who achieved an SVR despite a <3 log10 reduction in HCV RNA levels at 4 weeks had an arginine at residue 70 in the HCV core and a non-wild-type sequence for the ISDR of HCV NS5A.

Conclusion

A ≥3 log10 reduction in HCV RNA levels at 4 weeks after starting therapy indicates that a patient has a high likelihood of achieving an SVR as a final outcome. Additional information on the amino acid substitutions at residue 70 in the HCV core and within NS5A-ISDR will further increase the ability to predict a clinical response.

Keywords

Chronic hepatitis CFour weeksPeginterferonReduction in HCV RNAResponse-guided therapyRibavirin

Copyright information

© Springer 2010